Opinion on Genitourinary and Osteoporosis in South and Central America

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Abbott: safeguarding market leadership through elagolix deal

Global healthcare firm Abbott has boosted its gonadotropin releasing hormones pipeline through a deal with Neurocrine for the continued development of new promising candidate elagolix. The partnership is favorable for both parties, with Abbott seeking to maintain its endometriosis market leadership after Lupron's patent expiry in 2014.

Published By Datamonitor
17 Jun 2010
Expert View
Expert View

Amgen promotes novel offering at World Congress on Osteoporosis

The 2010 International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis in May was the most important meeting of the year in the osteoporosis arena. While no new groundbreaking data for the drug were revealed, Amgen used the congress to promote its novel monoclonal antibody denosumab.

Published By Datamonitor
18 May 2010
CommentWire
CommentWire

Amgen: denosumab deal maximizes potential in tough European market

Amgen has announced that it has formed a partnership with GlaxoSmithKline to commercialize denosumab for the treatment of postmenopausal osteoporosis in Europe and emerging markets. While this partnership increases denosumab's potential in the EU, the challenge will be to convince payers that the new monoclonal antibody provides a clear clinical advantage over cheap and effective alternatives.

Published By Datamonitor
29 Jul 2009
Expert View
Expert View

AUA 2010: companies aim to maintain presence in lucrative overactive bladder arena

Overactive bladder was a key area of focus at this year's meeting of the American Urological Association. In attending the conference, Datamonitor identified new strategies from Pfizer and Watson Pharmaceuticals which aim to put these companies' drugs at the forefront of treatment in this lucrative disease area.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

AUA 2010: encouraging new drugs in benign prostatic hyperplasia but challenges remain

Datamonitor attended this year's meeting of the American Urological Association, at which data were presented for two promising new candidates developed for the treatment of benign prostatic hyperplasia. Specifically, Watson Pharmaceuticals outlined the differentiators for its new treatment Rapaflo, while Nymox used the meeting to present new data for its pipeline drug NX-1207.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

FIGO 2009: Bayer-Schering maintains leadership in contraception

Datamonitor attended this year's International Federation of Gynecology and Obstetrics World Congress in Cape Town to assess the state of the women's healthcare market. The overwhelming presence of Bayer-Schering at the conference confirms the company's strength in the contraceptives field and its commitment to maintaining its market-leading position.

Published By Datamonitor
13 Oct 2009
Expert View
Expert View

FIGO 2009: expert backing for HRT for menopausal symptoms is welcome news

The debate regarding the use of HRT in postmenopausal women and its safety was very much a central topic throughout this year's International Federation of Gynecology and Obstetrics conference. Despite market-leader Wyeth's absence from the meeting, the core message that HRT should continue to be given to women in need will benefit players in this market.

Published By Datamonitor
13 Oct 2009
Expert View
Expert View

FIGO 2009: focus moves towards cervical cancer and overactive bladder

Among the key developments at this year's International Federation of Gynecology and Obstetrics meeting, pharmaceutical companies aimed to improve awareness of overactive bladder. Elsewhere, the reduction of mortality due to cervical cancer emerged as a key theme among delegates, with discussions of vaccine strategies not only in the developed world but also in developing countries.

Published By Datamonitor
13 Oct 2009
ResearchWire
ResearchWire

HRT market: innovative treatment options to restore growth

Published By Datamonitor
25 Apr 2008
CommentWire
CommentWire

Noven: Mesafem emerges as potential alternative to HRT

Recently announced results suggest that Noven's non-hormonal therapy Mesafem is effective in relieving vasomotor symptoms associated with the menopause. However, Datamonitor believes that Mesafem will have to demonstrate equivalent or superior efficacy to hormonal replacement therapy if it is to overcome the challenges in this underserved market.

Published By Datamonitor
17 Jul 2009

« | 1 | 2 | » »|

No help is available.